Thymulin
Thymulin (Facteur Thymique Serique, FTS-Zn, Serum Thymic Factor)
Zinc-dependent nonapeptide thymic hormone essential for T-cell maturation, with preclinical roles in anti-inflammatory, analgesic, and neuroendocrine signaling. Thymulin itself has never entered clinical trials (PMID 1418292; PMID 17192563; DOI 10.1007/s10989-024-10666-y).
Last updated: 2026-03-09
Safety Summary
In animal studies, low nanogram doses of thymulin administered locally (intraplantar) or systemically (intraperitoneal) produced hyperalgesia via PGE2-dependent mechanisms (PMID 17192563). At higher microgram doses, thymulin and its analogue PAT showed anti-inflammatory and analgesic effects without significant adverse effects (PMID 17192563). The 2025 review of thymic peptides noted that an important feature of thymus preparations is their therapeutic safety -- even long-term use does not cause side effects (DOI 10.1007/s10989-024-10666-y). The FDA FAERS database returned no adverse event reports for thymulin. In the topical zinc-thymulin hair loss application, community data reports no adverse systemic effects or local side effects across 3,300 applications (online communities/HairlossResearch). However, formal human safety data for exogenous thymulin injection is entirely lacking because thymulin has never entered clinical trials.
Known Side Effects
observed in animal studies at nanogram doses
Who Should NOT Use This
Thymulin promotes T-cell activation and maturation, which could theoretically trigger graft rejection in transplant recipients or counteract immunosuppressive therapy. This is a mechanism-based inference from established T-cell maturation role (PMID 1418292), not derived from clinical contraindication data. No thymulin-specific contraindication list exists.
Exogenous thymulin administration could theoretically exacerbate autoimmune responses by enhancing T-cell activity. Diminished thymulin has been observed in SLE and other autoimmune conditions (PMID 1418292). This is a mechanism-based inference, not derived.
Thymulin requires zinc binding for biological activity. Administration without adequate zinc status renders the peptide inactive (PMID 6791843; PMID 18054190). Zinc status should be assessed and corrected before or during thymulin use.
Talk to Your Doctor
Before considering Thymulin, discuss it with your healthcare provider. Ask about potential interactions with your current medications, whether it is appropriate for your health conditions, and what monitoring may be needed.
Sources: [1-10]
Evidence Assessment
Tier 4: No completed human clinical trials testing exogenous thymulin administration. The 2025 comprehensive review explicitly states that thymulin preparation never entered clinical trials (DOI 10.1007/s10989-024-10666-y). Extensive human observational data exists on serum thymulin levels in disease states (PMID 1418292; PMID 18054190). Strong preclinical evidence includes gene therapy models in animal asthma (PMID 24556417), analgesic/anti-inflammatory animal studies (PMID 17192563), and zinc supplementation studies showing restoration of thymulin activity (PMID 18054190; PMID 30697214). The sole ClinicalTrials.gov result (NCT01229579) is a zinc supplementation study in infants, not a direct thymulin trial. The basic science is extensive and well-established, but translation to exogenous human therapeutic use lacks Phase 1-3 trial data.
1Role of zinc and other metals in the biological activity of the serum thymic factor (thymulin)PMID 6791843
Dardenne M, Pleau JM, Lefrancier P et al. - C R Seances Acad Sci III (1981) - Biochemical mechanistic study - In vitro study
Demonstrated that FTS loses biological activity after chelation with Chelex 100. Activity is restored by zinc addition, establishing that thymulin exists in two forms: zinc-free (inactive) and zinc-bound (active). Proposed the name 'thymulin' for the active form.
Limitations: French-language paper; only short abstract available in downloaded file.
2Thymulin and its role in immunomodulationPMID 1418292
Safieh-Garabedian B, Kendall MD, Khamashta MA, Hughes GR - Journal of Autoimmunity (1992) - Narrative review - Review article
Comprehensive review establishing thymulin's role in T-cell differentiation, immunomodulation, and neuroendocrine interactions. Documented diminished thymulin levels in immunodeficiency and autoimmune disease.
Limitations: Narrative review, not primary research.
3Role of thymulin or its analogue as a new analgesic moleculePMID 17192563
Dardenne M, Saade N, Safieh-Garabedian B - Annals of the New York Academy of Sciences (2006) - Narrative review summarizing animal studies - Multiple animal experiments (rats)
Low-dose thymulin (nanograms) causes hyperalgesia via PGE2-dependent mechanisms. High-dose thymulin (1-25 micrograms) and analogue PAT reduce inflammatory pain and downregulate TNF-alpha, IL-1beta, IL-6. PAT showed analgesic effects equal to or stronger than standard anti-inflammatory drugs at lower concentrations. Intracerebroventricular thymulin inhibited NF-kappaB activation in hippocampus.
Limitations: Animal data only (rats). Preclinical review; no human thymulin trial data.
4Clinical, immunological, anti-inflammatory and antioxidant roles of zincPMID 18054190
Prasad AS - Experimental Gerontology (2008) - Narrative review covering human studies - Review covering multiple human studies including experimental zinc deficiency model and elderly supplementation trials
In experimental human zinc deficiency, thymulin activity was among the earliest markers to decrease, alongside decreased NK cell lytic activity and IL-2 activity. Zinc supplementation (45 mg/day) in elderly subjects decreased infections (7 vs 35 incidents over 12 months), restored thymulin activity, increased IL-2 mRNA, and decreased inflammatory cytokines.
Limitations: Focuses on zinc biology, not therapeutic thymulin administration. Thymulin discussed as a biomarker of zinc status.
5DNA nanoparticle-mediated thymulin gene therapy prevents airway remodeling in experimental allergic asthmaPMID 24556417
Da Silva AL et al. - Journal of Controlled Release (2014) - Animal study - Mouse model of allergic asthma
Single intranasal instillation of pDNA nanoparticle-mediated thymulin gene therapy improved lung function for up to 27 days by preventing lung inflammation, smooth muscle hypertrophy, and collagen deposition in allergic asthma model.
Limitations: Animal study (mice). Gene therapy delivery platform, not direct peptide administration.
6Thymic hormones. Neuroendocrine interactions and clinical use in congenital and acquired immune deficienciesPMID 6399194
Unknown (French-language publication) - Unknown (1984) - Review - Review article
Described the structure of four major thymic hormones including thymulin. Reviewed thymic hormone blood levels and clinical usefulness in congenital and acquired immunodeficiency states and autoimmune diseases. Described interactions between brain, thymus, and endocrine glands.
Limitations: French-language paper from 1984. Historical context.
7The Immune System in Children with Malnutrition--A Systematic ReviewPMID 25153531
Bourke CD et al. - PLoS ONE (2014) - Systematic review - Systematic review of 245 studies
Documented that thymulin levels are significantly reduced in malnourished children, contributing to impaired T-cell function and increased susceptibility to infections. Thymic atrophy in malnutrition correlates with decreased circulating thymulin.
Limitations: Systematic review covering malnutrition broadly; thymulin is one of many immune markers discussed.
8Nutritional Modulation of Immune Function: Analysis of Evidence, Mechanisms, and Clinical RelevancePMID 30697214
Wu D et al. - Frontiers in Immunology (2019) - Narrative review - Review article
Describes zinc as essential for thymulin activity and reviews evidence that zinc supplementation improves immune function in older adults, with thymulin activity as a key biomarker of zinc-immune interactions.
Limitations: Broad nutritional review; thymulin discussed as one component of zinc-immune biology.
9Review of Thymic Peptides and Hormones: From Their Properties to Clinical Application
Besman M, Zambrowicz A, Matwiejczyk M - International Journal of Peptide Research and Therapeutics (2025) - Narrative review - Review article
Describes thymulin as a zinc-dependent thymic epithelial nonapeptide with approximately 10.3-minute serum half-life, age-related decline, immune and neuroendocrine actions (CD90/CD3/CD4/CD8 expression, NK cell activity, LH/GH/PRL/TSH stimulation), and anti-inflammatory/analgesic properties. Explicitly states that thymulin preparation never entered clinical trials. Notes that thymic preparations have therapeutic safety -- even long-term use does not cause side effects.
Limitations: Secondary review source; does not provide primary clinical efficacy data for thymulin.
10Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in PakistanNCT01229579
Aga Khan University investigators - ClinicalTrials.gov record (2010) - Randomized controlled trial - 320 infants (planned)
Trial rationale states that zinc is an essential cofactor for thymulin and that zinc deficiency may suppress immunity, but thymulin itself was not the intervention.
Limitations: Assesses zinc sulfate rather than thymulin administration. Included because it is the only ClinicalTrials.gov result mentioning thymulin.